Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Lavanya Kundurthy currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by 1 distinct examiner, KLINKEL, KORTNEY L, within a distinct art unit. KLINKEL, KORTNEY L is the busiest examiner for the portfolio, managing 1 pending action.
This indicates that the current prosecution is entirely centralized. Practitioners can focus their strategy for the pending office action on the individual review style of KLINKEL, KORTNEY L. The presence of a single art unit suggests a narrow technical focus within the Biotechnology & Pharmaceuticals field. This streamlined arrangement simplifies the management of the 1 pending office action. The alignment of the busiest examiner's workload with the total pending actions ensures a clear point of contact within the patent office. This concentration allows for a highly targeted approach to the pending office action. The lack of multiple examiners or art units minimizes the complexity of managing the company's current patent interests. By focusing on the individual review style of the assigned examiner, the company can better anticipate procedural hurdles.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KLINKEL, KORTNEY L | 1 | 39.7% | +43.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18658098 | COMBINATION FORMULATIONS OF NALOXONE AND ATIPAMEZOLE | KLINKEL, KORTNEY L | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18658098 | COMBINATION FORMULATIONS OF NALOXONE AND ATIPAMEZOLE | KLINKEL, KORTNEY L | 1627 | §103 | Non-Final OA | — | Pending | May 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLavanya Kundurthy has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kortney L Klinkel has the most, with 1 of Lavanya Kundurthy's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
